Atreo

Atreo appears to be a legitimate B2B entity in the Randomization and Trial Supply Management (RTSM) space with a mid-sized team (29-55 employees), suggesting established operations and revenue. However, the submission quality is critically low, featuring demonstrable hallucinations (claiming 'most people' have used a specialized clinical trial product) and vague descriptors. While the underlying business likely possesses high utility and traction, the lack of verifiable evidence and the presence of false claims in the submission heavily penalize the score under the Proof of Usefulness framework.